Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 3/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.52 |
| ▸ | PPARG | P37231 | 3/20 | 0.52 |
| ▸ | CNR1 | P21554 | 5/20 | 0.43 |
| ▸ | CNR2 | P34972 | 5/20 | 0.43 |
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.38 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.38 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.38 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.38 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.38 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17558159 | 0.85 | CNR1 (0.47) | CNR1CNR2EPHX2MGLL | |
| SCHEMBL17558160 | 0.85 | CNR1 (0.47) | CNR1CNR2EPHX2MGLL | |
| SCHEMBL17558117 | 0.81 | MGLL (0.54) | CNR1CNR2EPHX2MGLLFAAH | |
| SCHEMBL19399338 | 0.81 | MGLL (0.54) | CNR1CNR2EPHX2MGLLFAAH | |
| SCHEMBL17577604 | 0.81 | CNR1 (0.48) | CNR1CNR2PPARA | |
| SCHEMBL26908492 | 0.80 | PTGES (0.57) | PTGESALOX5PPARGCNR1CNR2 | |
| SCHEMBL755408 | 0.80 | PPARA (0.48) | PTGESALOX5PPARGPPARATSHR | |
| SCHEMBL755409 | 0.80 | PPARA (0.48) | PTGESALOX5PPARGPPARATSHR | |
| SCHEMBL26908489 | 0.80 | PPARG (0.54) | PTGESALOX5PPARGCNR1CNR2 | |
| SCHEMBL17558149 | 0.79 | PPARG (0.43) | PTGESALOX5PPARGCNR1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10844002-B2 | Lipids and lipid compositions for the delivery of active agents | NOVARTIS AG (CH) | 2020-11-24 | — | — | US | disclosed |
| US-20190002393-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | NOVARTIS AG (CH) | 2019-01-03 | — | — | US | disclosed |
| US-10125092-B2 | Lipids and lipid compositions for the delivery of active agents | NOVARTIS AG (CH) | 2018-11-13 | — | — | US | disclosed |
| US-20170275243-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | NOVARTIS AG (CH) | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10844002-B2 | Lipids and lipid compositions for the delivery of active agents | LRAT, LIPA, LPAR1 | PTGES 2359/4885ALOX5 628/4885PPARG 597/4885 |
| US-20170275243-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | LRAT, LPAR4, LPAR1 | PTGES 2420/4885ALOX5 652/4885PPARG 626/4885 |
| US-10125092-B2 | Lipids and lipid compositions for the delivery of active agents | LRAT, LPAR4, LPAR1 | PTGES 2420/4885ALOX5 652/4885PPARG 626/4885 |
| US-20190002393-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | LRAT, LIPA, LPAR1 | PTGES 2359/4885ALOX5 628/4885PPARG 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.